A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
Clinical trial NCT01309789 · COMPLETED
Trial details
- NCT number
- NCT01309789
- Sponsor
- Seagen Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2013-04-01
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.